Pediatrics Doctors in Southbury, CT Accepting Medicare

4 Pediatrics doctors found. Showing 1 - 4

Susan Beris, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 22 Old Waterbury Rd # 204, Southbury, CT 06488 Phone: 203-262-4250

Lalaine Mortera, M.D. Pediatrics Medicare: Medicare Enrolled Practice Location: 22 Old Waterbury Rd, Suite 204, Southbury, CT 06488 Phone: 203-262-4250

Dr. Joseph M Tuggle, M.D. Pediatrics - Neonatal-Perinatal Medicine Medicare: Not Enrolled in Medicare Practice Location: 117 Charter Oak Rd, Southbury, CT 06488 Phone: 203-267-6644    Fax: 203-267-6646

Dr. Diana M Lippi, M.D. Pediatrics - Neonatal-Perinatal Medicine Medicare: Not Enrolled in Medicare Practice Location: 117 Charter Oak Rd, Southbury, CT 06488 Phone: 203-267-6644    Fax: 203-267-6646

News Archive

Enzyme that mutates antibodies also targets cancer-causing gene

The human immune system is in a perpetual state of self-experimentation. It expertly mutates and shuffles the DNA of its own cells to evolve new defenses against the vast array of microbes that try to invade our bodies.

BARDA awards GlaxoSmithKline contract for development of dual-purpose broad spectrum antibiotic

The federal government today issued a contract for advanced research and development of a dual-purpose broad spectrum antibiotic with potential to treat illnesses caused by bioterrorism threats such as plague and tularemia, as well as more certain life-threatening infections, known as Gram-negative infections, associated with prolonged hospitalization.

Deadline reportedly delayed for finalizing details with insurance plans on federal exchanges

Reuters reports these agreements are not likely to be signed until mid-September. Also in the news, the race is on to train navigators while, in Washington state, Group Health makes a decision about abortion coverage in exchange plans. And Republicans on Capitol Hill offer a new plan for insuring government officials.

ARYx Therapeutics receives guidance in writing from FDA on tecarfarin

ARYx Therapeutics, Inc., a biopharmaceutical company, today announced that is has received guidance in writing from the U.S. Food and Drug Administration (FDA) confirming that the existing development pathway remains acceptable to seek regulatory approval of ARYx's novel anticoagulant agent, tecarfarin (ATI-5923).

Health information technology gains momentum, uses

One in 10 doctors who work outside hospitals in the United States began using electronic health records in 2011, helped along by the promise of $27 billion in incentives from the federal government.

Read more Medical News

› Verified 4 days ago